Trial Profile
Study on clinical outcomes of viral hepatitis C, mechanism of difficult-to-treat hepatitis C and optimal therapeutic regimens.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 May 2012 Planned end date changed from 30 Jun 2010 to 30 Jun 2012 as reported by Chinese Clinical Trial Register.
- 25 Jul 2010 New trial record